Univ Supernumerary Fellow Professor Nicola R. Sibson and colleagues have just had a manuscript accepted by Nature Communications.
The manuscript reports on the development of a novel biodegradable MRI contrast agent that will allow them to translate their preclinical work in early diagnosis of brain metastasis (secondary cancer to the brain) to the clinic. This work is expected to go into clinical trial late in 2018, and is funded by the Medical Research Council under a Developmental Pathway Funding Scheme award.
Professor Sibson is Professor of Imaging Neuroscience and CRUK Senior Group Leader and Director of Graduate Studies at the CRUK/MRC Oxford Institute for Radiation Oncology.
Further details on Professor Nicola R. Sibson here.